Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–2 of 2 stories
A new proposal outlines diagnostic criteria for chronic graft-versus-host disease manifestations in the peripheral nervous system and muscles. This initiative aims to enhance the understanding and diagnosis of this complex condition.
Read full storyIbrutinib (Imbruvica) has received both Breakthrough Therapy and Orphan Drug designations for treating chronic graft-versus-host disease (cGVHD) as a monotherapy. This designation highlights its potential for patients who have not responded to previous therapies.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.